Clinical Response With Pembrolizumab for Cutaneous Squamous Cell Carcinoma

被引：2

作者：

Corbett, Mel ^{[1
,4
]}

Tohani, Shivangy ^{[1
]}

Ramli, Ruzaimi ^{[1
]}

O'Duffy, Fergal ^{[1
,2
,3
]}

机构：

[1] Univ Coll Dublin, Head & Neck Oncol Grp, Dublin, Ireland

[2] St Vincents Univ Hosp, Dept Head & Neck Surg, Dublin, Ireland

[3] Mater Misericordiae Univ Hosp, Dept Head & Neck Surg, Dublin, Ireland

[4] St Vincents Univ Hosp, Elm Pk, Dublin, Ireland

来源：

JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY | 2024年 / 150卷 / 06期

关键词：

D O I：

10.1001/jamaoto.2024.0544

中图分类号：

R76 [耳鼻咽喉科学];

学科分类号：

100213 ;

摘要：

This case report describes an 89-year-old patient with prior cutaneous squamous cell carcinoma who presented with a new isolated metastasis and was subsequently treated with pembrolizumab, which produced a complete clinical response.

引用

页码：524 / 525

页数：2

共 50 条

[31] Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC).
Haddad, Robert I.
Seiwert, Tanguy Y.
Chow, Laura Quan Man
Gupta, Shilpa
Weiss, Jared
Gluck, Iris
Eder, Joseph Paul
Burtness, Barbara
Tahara, Makoto
Keam, Bhumsuk
Kang, Hyunseok
Muro, Kei
Albright, Andrew
Huang, Lingkang
Ayers, Mark
Mogg, Robin
Cristescu, Razvan
Cheng, Jonathan D.
Mehra, Ranee
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[32] Regression of cutaneous squamous cell carcinoma after the development of pembrolizumab-induced bullous pemphigoid
Iinuma, Shin
Hayashi, Kei
Ishida-Yamamoto, Akemi
JEADV CLINICAL PRACTICE, 2023, 2 (01): : 136 - 139
[33] Efficacy of pembrolizumab in a patient with xeroderma pigmentosum variant and advanced cutaneous squamous-cell carcinoma
Hennemann, Aymeric
Collonge Rame, Marie Agnes
Puzenat, Eve
Ged, Cecile
Harbon, Sylvain
Aubina, Francois
Nardin, Charlee
ACTA ONCOLOGICA, 2022, 61 (09) : 1140 - 1142
[34] Pembrolizumab for the Treatment of Locally Advanced Cutaneous Squamous Cell Carcinoma: Patient Selection and Special Considerations
Stewart, Matthew
Geiger, Jessica L.
CANCER MANAGEMENT AND RESEARCH, 2025, 17 : 211 - 217
[35] CARSKIN: Pembrolizumab as first line therapy in patients with unresectable cutaneous squamous cell carcinoma (cSCC).
Maubec, Eve
Helfen, Sabine
Scheer-Senyarich, Isabelle
Boubaya, Marouane
Schischmanoff, Olivier
Alloux, Celine
Deschamps, Lydia
Petrow, Peter
Lopez, Isabelle
Tibi, Annick
Levy, Vincent
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[36] Case report: Increased efficacy of cetuximab after pembrolizumab failure in cutaneous squamous cell carcinoma
Morecroft, Renee
Phillipps, Jordan
Zhou, Alice
Butt, Omar
Khaddour, Karam
Johanns, Tanner
Ansstas, George
FRONTIERS IN ONCOLOGY, 2024, 14
[37] Expression of Programmed Cell Death Ligand in Cutaneous Squamous Cell Carcinoma and Treatment of Locally Advanced Disease With Pembrolizumab
Stevenson, Mary L.
Wang, Claire Q. F.
Abikhair, Melody
Roudiani, Nazanin
Felsen, Diane
Krueger, James G.
Pavlick, Anna C.
Carucci, John A.
JAMA DERMATOLOGY, 2017, 153 (04) : 299 - 303
[38] Cancer cell plasticity defines response to immunotherapy in cutaneous squamous cell carcinoma
Lorenzo-Sanz, Laura
Lopez-Cerda, Marta
da Silva-Diz, Victoria
Artes, Marta H.
Llop, Sandra
Penin, Rosa M.
Bermejo, Josep Oriol
Gonzalez-Suarez, Eva
Esteller, Manel
Vinals, Francesc
Espinosa, Enrique
Oliva, Marc
Piulats, Josep M.
Martin-Liberal, Juan
Munoz, Purificacion
NATURE COMMUNICATIONS, 2024, 15 (01)
[39] Prolonged Response to Pembrolizumab in Spindle Cell Squamous Cell Carcinoma Metastatic to the Central Nervous System
Liu, Yuxin
Fitzgerald, Bailey
Perry, Edward
Pathak, Ashutosh
Chao, Herta H.
JOURNAL OF INVESTIGATIVE MEDICINE HIGH IMPACT CASE REPORTS, 2019, 7
[40] PERINEURAL INFILTRATION OF CUTANEOUS SQUAMOUS CELL CARCINOMA AND BASAL CELL CARCINOMA WITHOUT CLINICAL FEATURES
Lin, Charles
Tripcony, Lee
Keller, Jacqui
Poulsen, Michael
Martin, Jarad
Jackson, James
Dickie, Graeme
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (01): : 334 - 340

← 1 2 3 4 5 →